Hospitals Segment to Dominate Middle East & Africa Low Molecular Weight Heparin Market during 2019–2028

According to a new market research study on “Middle East & Africa Low Molecular Weight Heparin Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product Type, Packaging, Application, and End User,” is expected to reach US$ 213.01 million by 2028 from US$ 151.20 million in 2021. The market is estimated to grow at a CAGR of 5.0% from 2021 to 2028. Introduction of LMWH anticoagulants is the major factor driving the growth of the Middle East & Africa low molecular weight heparin market. However, adverse effects of low molecular weight heparin during treatment may hinder the growth of Middle East & Africa low molecular weight heparin market. The report provides trends prevailing in the Middle East & Africa low molecular weight heparin market along with the drivers and restraints pertaining to the market growth.

The COVID-19 pandemic has increased demand for in-home medical care devices. With an increase in the number of patients admitted to intensive care units (ICU), the rise in the number of drugs that pose multiple diagnostic and therapeutic challenges to strained health systems is boosting the demand for medical devices in the region. There have been changes in staff assignments and their working hours, and infection control strategies, with the enactment of social distancing measures. In addition, healthcare service providers also face mental, physical, emotional, and financial challenges. Anticoagulation therapy with low molecular weight heparin (LMWH) is particularly recommended at the early stages of the disease. Infections are a common cause of disseminated intravascular coagulation. Inflammations and infections can lead to excessive activation of clotting. Current treatment of severe and critical type COVID-19 patients in the Middle East & Africa are mainly leading to the rising number of deaths. Doctors recommend the early initiation of IVIg and LMWH anticoagulant therapy, which effectively improves the prognosis of patients with severe and critical types. More immunity-related research is needed to help people understand pathogenesis, come up with specific treatment for the disease, and understand prognosis better to greater depths.

The Middle East & Africa low molecular weight heparin market is segmented into product type, packaging, application, end user and country. The Middle East & Africa low molecular weight heparin market, based on product type, has been segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others. The enoxaparin segment held the largest share of the market in 2021. The Middle East & Africa low molecular weight heparin market based on packaging is segmented into multi-vials and prefilled syringes. In 2021, the multi-vials segment held the largest share of the market. The Middle East & Africa low molecular weight heparin market, based on application, has been segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. The Middle East & Africa low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. Similarly, based on country, the market is bifurcated into Saudi Arabia, South Africa, UAE, and rest of MEA. Saudi Arabia held the largest share of the Middle East & Africa low molecular weight heparin market in 2021. 

Abbott, Aspen Holdings, B. Braun Medical Inc., Dr. Reddy's Laboratories, LEO Pharma A/S, Novartis, Pfizer Inc., Sanofi, and TEVA PHARMACEUTICAL INDUSTRIES LTD are among the leading companies in the Middle East & Africa Low Molecular Weight Heparin Market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2018, Dr Reddy's Laboratories Ltd has launched the antiepileptic drug, Levetiracetam in Sodium Chloride Injection, in multiple strengths.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com